Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | TSHR | P16473 | 4/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL486054 | 0.93 | NPSR1 (0.97) | NPSR1ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL486082 | 0.93 | NPSR1 (0.90) | NPSR1ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL486075 | 0.91 | NPSR1 (1.00) | NPSR1ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL12869185 | 0.82 | NPSR1 (0.73) | NPSR1ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL486405 | 0.76 | LMNA (0.59) | NPSR1ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL12820989 | 0.76 | NPSR1 (0.64) | NPSR1ALDH1A1TSHRLMNAKDM4E | |
| SCHEMBL12869168 | 0.73 | LMNA (0.83) | NPSR1ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL486154 | 0.72 | NPSR1 (0.56) | NPSR1ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL486694 | 0.72 | LMNA (0.74) | NPSR1ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL13284544 | 0.72 | LMNA (0.54) | NPSR1ALDH1A1TSHRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2145884-B1 | INDOLEDIONE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8106086-B2 | Indoledione derivative | MSD K.K. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20100056597-A1 | INDOLEDIONE DERIVATIVE | MSD K.K. (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2145884-A1 | INDOLEDIONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056597-A1 | INDOLEDIONE DERIVATIVE | LIPE, IDO1, ADRA1A | NPSR1 761/4885ALDH1A1 303/4885TSHR 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.